Efficacy and safety of saxagliptin in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- At: 2016 FIP Congress in Buenos Aires (Argentina)
- Type: Poster
- By: ZHAI, Suo-Di (Peking University Third Hospital, Department of Pharmacy, BEIJING, China)
- Co-author(s): Peng Men:Department of Pharmacy,Peking University Third Hospital,BEIJING,China|Hui-Lin Tang:Department of Pharmacy,Peking University Third Hospital,BEIJING,China|Suo-Di Zhai:Department of Pharmacy,Peking University Third Hospital,BEIJING,China
There is a need for state-of-the-art evidence to inform clinical decisions about differences among various antidiabetic drugs.
A systematic search was performed of PubMed, Embase, the Cochrane Library, Web of Science, and 2 Chinese databases for RCTs comparing saxagliptin with placebo or active comparators, both as monotherapy and add-on.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.